Could white blood cells drive skin scarring in scleroderma?
NCT ID NCT03816189
First seen Jan 10, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This completed study examined whether eosinophils, a type of white blood cell, contribute to fibrosis (scarring) in systemic sclerosis, an autoimmune disease. Researchers compared blood samples from 40 patients with systemic sclerosis and 30 healthy volunteers, with optional skin biopsies. The goal was to understand how eosinophils might promote tissue damage, which could inform future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could point toward new targets for treating fibrosis in systemic sclerosis.
What could go wrong
This is an observational study with only 70 participants, so findings may not apply broadly or lead directly to treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.